AI Platform Licensing Proprietary asymmetrical gene-silencing aiRNA along with novel nanotechnology and synthetic biology platforms creates licensing and co-development opportunities for pharma and biotech partners seeking novel therapeutics and delivery technologies.

Academic Industry The hybrid academia-industry culture enables strong potential for sponsored research, joint translational projects, and collaborations with nearby universities and research institutes to de-risk early-stage programs and accelerate proof-of-concept.

Boston Proximity Located in Norwood, MA with access to the greater Boston biotech ecosystem, offering proximity to talent pools, CROs/CMOs, and regulatory experts to support accelerated development timelines and scale-up partnerships.

Growth Partnership Readiness As a mid-sized biotech with a focused R&D agenda, the company is well-positioned for scalable partnerships, pilot engagements, and technology validation deals with contract service providers and platform suppliers.

Integrated Team An experienced team spanning research, product development, finance, and clinical affairs can manage end-to-end engagements from discovery through translation, appealing to partners needing integrated program management and regulatory strategy.